Condition 1: Ulcerative (chronic) rectosigmoiditis. Condition 2: Left sided colitis, left hemicolitis. Ulcerative (chronic) rectosigmoiditis Left sided colitis
Conditions
Interventions
Intervention 1: Intervention group: Ulcerative colitis patients in the intervention group will receive Mesalazine as standard treatment (3g/daily) combined with 300 mg/daily of Mebendazole orally. Int
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Provide written documentation of informed consent to participate in the study. Male or female aged 18 to 60 years. Subjects with a confirmed diagnosis of moderate proctosigmoiditis and Left-sided colitis. Diagnosis established by endoscopy and histology. Participants have no proven current active gastrointestinal infection.
Exclusion criteria
Exclusion criteria: Subjects with Crohn's disease or other types of colitis including Infectious, Radiation or Ischemic colitis. Allergy to Mesalamine or Mebendazole. Subjects who have a positive pregnancy test, or breast feeding. Subjects treated with immuno-modulatory drugs from two months before screening or receiving pro- or antibiotics from two weeks from screening. Patients who have already received metronidazole or Mebendazole for parasitic worm infection. Subjects with leukopenia, thrombocytopenia, neutropenia, Hb< 10 Subjects with Chronic Medical Conditions including heart diseases, lung diseases esp. Tuberculosis, Renal dysfunction, liver diseases, coagulation disorders, Drug abuse Patients with Ulcerative Proctitis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical Symptoms including weight loss, fever, bowel movement frequency, Stool consistency, Presence or absence of blood in feces, Mucus in feces. Timepoint: Before intervention, 1, 2 and 3 months after intervention. Method of measurement: Will be evaluated by physician. | — |
Secondary
| Measure | Time frame |
|---|---|
| Laboratory Findings including measurement of Aspartate transaminase, Alanine transaminase, Alkaline phosphatase, total and direct bilirubin, albumin, urea, creatinine, sodium, potassium, complete blood count, prothrombin time, partial thromboplastin time, international normalized ratio, total iron-binding capacity, iron, erythrocyte sedimentation rate, C-reactive protein, fecal calprotectin, and stool culture. Timepoint: Before intervention, 1, 2 and 3 months after intervention. Method of measurement: Standard laboratory methods.;Histological findings including functional and cytological changes in crypts, presence of Paneth cells, alterations in mucus and sub-mucus, presence of crypt abscess, Cryptitis, reduction in intraepithelial muscins, presence of eosinophils in lamina propria, Basal Plasmacytosis and basal lymphoid aggregates. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Histology. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Mahdi Hassanian Mehr
Mashhad University of Medical Sciences
Outcome results
None listed